Trials / Completed
CompletedNCT01663740
A Study on Spermatogenesis in Male Renal Transplant Recipients Receiving Valganciclovir (Valcyte®) Versus Untreated Matched Controls
A Multicenter Prospective Cohort Study to Investigate if Ganciclovir Significantly Affects Spermatogenesis in Adult Male Renal Transplant Recipients Receiving up to 200 Days Valganciclovir Vs. Concurrent Untreated Matched Controls
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 59 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- Male
- Age
- 20 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
This observational study will compare spermatogenesis in male adult renal transplant recipients receiving valganciclovir versus untreated matched controls. Data will be collected from each participant for up to 52 weeks post transplant.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Valganciclovir | Participants will receive valganciclovir 900 milligrams (mg) orally once daily for up to a maximum of 200 days post-transplant. |
Timeline
- Start date
- 2012-01-30
- Primary completion
- 2015-09-29
- Completion
- 2016-12-30
- First posted
- 2012-08-13
- Last updated
- 2018-08-31
- Results posted
- 2018-08-31
Locations
19 sites across 2 countries: United States, Mexico
Source: ClinicalTrials.gov record NCT01663740. Inclusion in this directory is not an endorsement.